3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow BioNTech Research & Development, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy MVT-1075, MVT-5873 - Pancreatic Carcinoma, Tumors That Express CA 19-9 | Phase 1 | Terminated | BioNTech Research & Development, Inc. | 4 | 2017-06-01 | 2023-04-21 |
| Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 MVT-2163, MVT-5873 - Pancreatic Carcinoma, Tumors That Express CA19-9 | Phase 1 | Terminated | BioNTech Research & Development, Inc. | 15 | 2016-07-11 | 2021-08-31 |
| Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel - Pancreatic Cancer | Phase 1 | Terminated | BioNTech Research & Development, Inc. | 118 | 2016-01-01 | 2025-01-28 |
130-nm albumin-bound paclitaxel (1) · Gemcitabine (1)
United States (3)